NovoCure (NASDAQ:NVCR) Given New $27.00 Price Target at Wedbush

NovoCure (NASDAQ:NVCR) had its price target trimmed by Wedbush from $29.00 to $27.00 in a research note published on Wednesday, Marketbeat.com reports. The firm currently has a neutral rating on the medical equipment provider’s stock. Wedbush also issued estimates for NovoCure’s Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.72) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.87) EPS, Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.74) EPS and FY2027 earnings at ($2.64) EPS.

NVCR has been the topic of several other research reports. JPMorgan Chase & Co. decreased their price objective on NovoCure from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Thursday, April 10th. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of NovoCure in a report on Tuesday, January 14th. Finally, StockNews.com cut shares of NovoCure from a “hold” rating to a “sell” rating in a research note on Wednesday, April 9th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.17.

NovoCure Trading Down 1.6 %

NovoCure stock opened at $15.58 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.71 billion, a P/E ratio of -11.13 and a beta of 0.65. The business has a 50-day simple moving average of $18.95 and a two-hundred day simple moving average of $21.54. NovoCure has a 52-week low of $11.70 and a 52-week high of $34.13.

NovoCure (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.27). The business had revenue of $161.27 million during the quarter, compared to the consensus estimate of $161.30 million. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. Analysts predict that NovoCure will post -1.3 EPS for the current year.

Hedge Funds Weigh In On NovoCure

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GeoWealth Management LLC purchased a new stake in shares of NovoCure during the 4th quarter worth approximately $27,000. Lindbrook Capital LLC lifted its position in NovoCure by 189.2% during the fourth quarter. Lindbrook Capital LLC now owns 1,854 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 1,213 shares during the last quarter. Blue Trust Inc. grew its stake in shares of NovoCure by 70.7% in the 4th quarter. Blue Trust Inc. now owns 1,886 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 781 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of NovoCure during the 4th quarter valued at about $68,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of NovoCure in the 4th quarter valued at about $70,000. 84.61% of the stock is owned by institutional investors.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.